Rezolute Inc is trading 5.2% up at $4.06 as the stock stages a recovery following recent weakness over the past week.
- No fresh company announcements, FDA updates, or analyst rating changes have been reported so far on June 12, 2026.
- The price action appears to be a technical bounce typical of low-float biotech stocks rather than a reaction to a clearly identified new catalyst.